Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Raymond Meng"'
Autor:
Namrata Patil, Raymond Meng, Robert Johnston, Patrick Chang, Shyam Srivats, Yoonha Choi, Xiangnan Guan, Barzin Nabet, Lisa McGinnis, Eugene Chiang, Thinh Pham, Alexis Dunkle, Bill O’Gorman, Ira Mellman, Ruozhen Hu, John Silva, Joy Han, Amelia Au-Yeung, Chikara Takahashi, Nandini Molden, Pallavi Daggumati, Wendy Connolly, Melissa Johnson, Delvys Rodriguez Abreu, Byoung Chul Cho, Antoine Italiano, Ignacio Gil Bazo, Enriqueta Felip, Sanjeev Mariathasan, Carlos Bais, David Shames
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96092dc69ac774aa79e80814a01152e2
https://doi.org/10.1136/jitc-2022-sitc2022.0475
https://doi.org/10.1136/jitc-2022-sitc2022.0475
Autor:
Namrata S. Patil, Shyam Srivats, Yoonha Choi, Xiangnan Guan, Barzin Nabet, Lisa McGinnis, Eugene Chiang, Alexis Dunkle, Bill O’Gorman, Patrick S. Chang, Ruozhen Hu, John Silva, Joy Han, Amelia Au-Yeung, Chikara Takahashi, Nandini Molden, Pallavi Daggumati, Wendy Connolly, Melissa Johnson, Delvys Rodriguez Abreu, Byoung Chul Cho, Antoine Italiano, Ignacio Gil-Bazo, Enriqueta Felip, Ira Mellman, Raymond Meng, Sanjeev Mariathasan, Robert Johnston, David S. Shames
Publikováno v:
Cancer Research. 83:5712-5712
Background: TIGIT is a co-inhibitory receptor and immune checkpoint associated with T cell and natural killer (NK) cell dysfunction in cancer. Tiragolumab is an anti-TIGIT antibody with an active IgG1/kappa Fc. In a randomized double-blind phase 2 cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24753044e2fa90ac2e90572444b63dbf
https://doi.org/10.1158/1538-7445.am2023-5712
https://doi.org/10.1158/1538-7445.am2023-5712
Autor:
Charles M. Rudin, Stephen V. Liu, Shun Lu, Ross A. Soo, Min Hee Hong, Jong-Seok Lee, Maciej Bryl, Daphne W Dumoulin, Achim Rittmeyer, Chao-Hua Chiu, Ozgur Ozyilkan, Alejandro Navarro, Silvia Novello, Yuichi Ozawa, Raymond Meng, Tien Hoang, Anthony Lee, Xiaohui Wen, Meilin Huang, Martin Reck
Publikováno v:
Journal of Clinical Oncology. 40:LBA8507-LBA8507
LBA8507 Background: Atezo, in combination with CE, was the first cancer immunotherapy approved for 1L treatment of ES-SCLC. However, most pts eventually experience disease progression. TIGIT is a novel inhibitory immune checkpoint present on activate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28dc136a7a7163c80ed6499c080cd545
https://doi.org/10.1200/jco.2022.40.17_suppl.lba8507
https://doi.org/10.1200/jco.2022.40.17_suppl.lba8507
Autor:
Johanna C. Bendell, Philippe Bedard, Yung-Jue Bang, Patricia LoRusso, Stephen Hodi, Michael Gordon, Sandra D'Angelo, Jayesh Desai, Elena Garralda, Antoine Italiano, Myung-Ju Ahn, Andres Cervantes, Zev Wainberg, Emiliano Calvo, Marta Gil-Martin, Maria Martinez-Garcia, Rastilav Bahleda, Philippe Cassier, Jean-Pierre Delord, Amy Prawira, Ignacio Melero, Leisha Emens, Emanuela Romano, Karen Miller, Robert W. Hsieh, Cloris Xue, Kari Morrissey, Patrick Twomey, Kelly Gash, Namrata S. Patil, Jane Grogan, Raymond Meng, Byoung Cho, Tae Won Kim
Publikováno v:
Cancer Research. 80:CT302-CT302
Background: The immunomodulatory receptor TIGIT (T-cell Immunoreceptor with Ig and ITIM domains) is a novel inhibitory immune checkpoint present on activated T cells and NK cells in multiple cancers. In preclinical models, co-inhibition of the TIGIT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db31a81666212efcd4b8e83e3dc853e8
https://doi.org/10.1158/1538-7445.am2020-ct302
https://doi.org/10.1158/1538-7445.am2020-ct302
Publikováno v:
Annals of the New York Academy of Sciences. 650:132-139
The effects of alprazolam (ALP), a triazolobenzodiazepine with high affinity for "central" benzodiazepine receptors, were examined on several parameters of immune function in mice. NK, MLR, and mitogen-induced lymphocyte proliferation were all signif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f4a4c7a0e7df235f0940c47feb82076
https://doi.org/10.1111/j.1749-6632.1992.tb49110.x
https://doi.org/10.1111/j.1749-6632.1992.tb49110.x